Pharmacogenomics Education Program (PharmGenEd)

"Pharmacogenomics Education Program (PharmGenEd): Bridging the Gap between Science and Practice" is an evidence-based program designed for pharmacists and physicians, pharmacy and medical students, nurses, and genetic counselors. The program team at UCSD Skaggs School of Pharmacy and Pharmaceutical Sciences collaborates with healthcare professional schools and organizations to disseminate educational materials. PharmGenEd is a comprehensive pharmacogenomics educational program. No membership is required, but users must complete free online registration in order to view lecture videos and handouts. In addition, licensed health care professionals may use components of PharmGenEd to teach others as long as they agree to an end-user license agreement and meet specified requirements. Authors are pharmacogenomics experts from multiple academic institutions and affiliations. Educational materials are produced by the authors and the program core team members from the University of California, San Diego (UCSD) Skaggs School of Pharmacy and Pharmaceutical Sciences (SSPPS) and the School of Medicine. A shared curriculum platform to provide open-access educational materials for students and trainers. PharmGenEd website includes lecture videos and handouts. Using the "Train-the-Trainer" approach, PharmGenEd also provides teaching materials to healthcare professional faculty. Additional resources include lists of News and Publications, References, EGAPP Recommendations, Textbooks, Journal Article References, and links to other genomics websites and training resources.

Type Website
CME Available No
Cost Free
Note Lecture videos, Handouts
Date of Resource 2016

Genomic Competencies

Experts from the disciplines listed below have tagged this resource as fulfulling genomic competencies.


  • Basic Genetic Concepts
    • B1:   To demonstrate an understanding of the basic genetic/genomic concepts and nomenclature
    • B2:   To recognize and appreciate the role of behavioral, social, and environmental factors (lifestyle, socioeconomic factors, pollutants, etc.) to modify or influence genetics in the manifestation of disease
  • Ethical, Legal and Social Implications (ELSI)
    • E1:   To understand the potential physical and/or psychosocial benefits, limitations and risk of genomic/pharmacogenomic information for individuals, family members and communities, especially with genomic/pharmacogenomic tests that may relate to predisposition to disease
    • E4:   To appreciate the cost, cost-effectiveness, and reimbursement by insurers relevant to genomic or pharmacogenomic tests and test interpretation, for patients and populations
  • Genetics and Disease
    • G3:   To appreciate that pharmacogenomic testing may also reveal certain genetic disease predispositions (e.g. the Apo E4 polymorphism)
  • Pharmacogenetics/Pharmacogenomics
    • P1:   To demonstrate an understanding of how genetic variation in a large number of proteins, including drug transporters, drug metabolizing enzymes, direct protein targets of drugs, and other proteins (e.g. signal transduction proteins) influence pharmacokinetics and pharmacodynamics related to pharmacologic effect and drug response
    • P2:   To understand the influence (or lack thereof) of ethnicity in genetic polymorphisms and associations of polymorphisms with drug response
    • P3:   Recognize the availability of evidence based guidelines that synthesize information relevant to genomic/pharmacogenomic tests and selection of drug therapy (e.g. Clinical Pharmacogenomics Implementation Consortium)